<DOC>
	<DOCNO>NCT00842712</DOCNO>
	<brief_summary>Primary objective study 's Safety run-in : - To determine maximum tolerate dose ( MTD ) cilengitide combination cetuximab , platinum-based chemotherapy ( cisplatin/vinorelbine cisplatin/gemcitabine ) . Primary objective study 's Randomization Part : - To assess efficacy cilengitide combination cetuximab platinum-based chemotherapy ( cisplatin/vinorelbine cisplatin/gemcitabine ) compare cetuximab platinum-based chemotherapy alone term progression-free survival ( PFS ) time . Study design plan : This multicenter , open-label , randomize , control Phase II study safety run-in part subject advance non-small cell lung cancer ( NSCLC ) . During safety run-in , regimen intensify stepwise cohort ( cilengitide intravenous [ i.v . ] 1000 milligram [ mg ] 2000 mg twice week ) classical 3+3 subject ( platinum-based chemotherapy regimens separately ) approach predefined dose- schedule reduction rule . In safety run-in 12 subject include evaluated safety feasibility different escalate dos cilengitide administer twice weekly combination cetuximab , cisplatin vinorelbine gemcitabine . After completion safety run-in , randomize part start , subject receive cetuximab platinum-based chemotherapy ( cisplatin/vinorelbine cisplatin/gemcitabine ) . Subjects centrally randomize 1:1 basis either Group A C ; Group B close implementation Amendment No . 4 ( date 20 December 2010 ) : • Group A : Cilengitide 2000 mg weekly ( Days 1 , 8 , 15 every 3-week chemotherapy cycle ) combination cetuximab platinum-based chemotherapy consist follow : - Cetuximab weekly ( Days 1 , 8 , 15 ) , plus cisplatin Day 1 vinorelbine Days 1 8 every 3-week chemotherapy cycle , - Cetuximab weekly ( Days 1 , 8 , 15 ) , plus cisplatin Day 1 gemcitabine Days 1 8 every 3-week chemotherapy cycle . The decision 2 chemotherapy regimen apply give subject discretion treat investigator . • Group B : Cilengitide 2000 mg twice weekly ( Days 1 , 4 , 8 , 11 , 15 , 18 every 3-week chemotherapy cycle ) combination cetuximab platinum-based chemotherapy describe Group A . Group B close implementation Amendment No . 4 ( global , date 20 December 2010 ) . Subjects randomize Group B implementation Amendment No 4 continue treat plan . • Group C : Cetuximab platinum-based chemotherapy describe Group A Chemotherapy give radiographically document progressive disease ( PD ) unacceptable toxicity 6 cycle . Cilengitide cetuximab give radiographically document PD unacceptable toxicity . Randomization perform centrally use interactive voice/web response system ( IXRS ) . A stratified block randomization procedure employ use choose first-line chemotherapy ( cisplatin/vinorelbine versus cisplatin/gemcitabine ) stratification criterion .</brief_summary>
	<brief_title>Cilengitide Cetuximab Combination With Platinum-based Chemotherapy First-line Treatment Subjects With Advanced Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Schedule visit assessment : Pre-screening Visit ( Within 2 week prior screen ) : In initial step subject newly diagnose NSCLC ( suspect already establish diagnosis ) offer tumor assess locally Epidermal Growth Factor Receptor ( EGFR ) expression . After give specific write informed consent analysis , formally registered tissue analyze . Signing informed consent local immunohistochemistry ( IHC ) base EGFR expression determination ; EGFR expression test local pathology laboratory use archived tumor material ; Demographics , , subject initial , date birth , gender , ethnicity/race , height ; Allocation subject number ; Date initial diagnosis ; Tumor characteristic ( histology , localization , metastasis , Tumor-Nodes-Metastases ( TNM ) classification ) . Screening Visit ( Within 3 week prior randomization ) : Signing informed consent study participation ( pre-screening positive EGFR expression &gt; =200 ) ; Archived tumor material biomarker analysis include EGFR , k-ras , b-raf , pathology possible additional biomarker research include mutation testing ; Relevant medical history ; Prior treatment underlie tumor ; Physical examination include vital sign ( include body weight , without body surface area [ BSA ] ) ; ECOG-performance status ; Central 12-lead electrocardiogram ( ECG ) ; Pulmonary function test ; Baseline image within 4 week prior randomization ( RECIST ) : At least chest + abdomen compute tomography ( CT ) ( magnetic resonance image [ MRI ] contraindication CT ) ; Documentation concomitant medication adverse event ( AEs ) ; Safety laboratory assessment ( hematology include coagulation parameter biochemistry ) ; Blood sample Human anti-chimeric antibody ( HACA ) assessment ; Serum pregnancy test woman childbearing potential within 7 day start study medication ; In-/exclusion criterion review ; Randomization , ( perform &lt; =7 day start therapy ) ; Optional : additional write informed consent pharmacogenetics test optional : blood sample pharmacogenetics test ( applicable randomize study part ) . Day 1 Each Cycle ( Start Cycle Visit ) ( At start chemotherapy cycle ) Before start first cycle : randomization perform &lt; =7 day start therapy ; Physical examination include vital sign ( include body weight BSA ) ; Assessment cardiovascular specific symptom ; Documentation AEs ; Concomitant medication ; Safety laboratory assessment ( hematology include coagulation parameter biochemistry ) must available start chemotherapy ; Central Holter ECG start treatment end infusion cilengitide ( Group C subject 1 hour end infusion cetuximab ) Day 1 first cycle ; Central standard ECG Cycles 2-6 ; ECOG-performance status ; Administration cilengitide ( Groups A B ) ; Administration cetuximab ( subject ) ; Administration cisplatin/vinorelbine cisplatin/gemcitabine ( subject ; first 6 cycle ) ; Blood sample plasma circulate marker ( Day 1 Cycle 1 pre-dose end cisplatin infusion ) ; Additional blood sample Common Toxicity Criteria ( CTC ) /circulating endothelial cell ( CEC ) assessment ( pre-dose Day 1 Cycle 1 Cycle 2 ) ; Blood sample cilengitide pharmacokinetic ( PK ) ( 6-10 subject Group B ; Cycle 1 ; see Section 7.4.1 detail ) ( dedicate site ) ; Blood sample cetuximab PK ( subject Group A ; Cycles 1 2 ) ; Blood sample vinorelbine PK ( 6-10 subject Groups B C ; Cycle 1 ) ( dedicate site ) . Days 4 , 11 18 Days 4 , 11 , 18 Each Cycle ( Group B ) Vital sign ( without BSA/body weight ) ; Administration cilengitide . Days 4 11 ( additional examination first 2 week first cycle safety run-in ) : safety laboratory assessment ( hematology include coagulation parameter biochemistry ) . Days 8 15 Days 8 15 Each Cycle : Vital sign ( without BSA/weight ) ; assessment cardiovascular specific symptom ; documentation AEs ; concomitant medication ; administration cilengitide ( Groups A B ) ; administration cetuximab ; administration vinorelbine gemcitabine ( subject ; Day 8 first 6 cycle ) ; blood sample pro-brain natriuretic peptide ( proBNP ) ( Cycle 1 Day 8 ) ; blood sample cetuximab PK ( subject Group A ; Days 8 15 Cycle 1 Day 8 Cycle 2 ) ; blood sample plasma circulate marker ( subject ; Days 8 15 first cycle pre dose , subsequent cycle Day 8 ) . Days 8 15 ( additional examination safety run-in ) : safety laboratory assessment ( hematology include coagulation parameter biochemistry ) must available start chemotherapy . Once weekly safety lab evaluation safety run-in ( end chemotherapy ) : safety laboratory assessment ( hematology include coagulation parameter biochemistry ) . 6-weekly Evaluation Visit ( Every 6 week +/- 2 day randomization final tumor assessment ( FTA ) visit ) : Physical examination include vital sign ( without BSA/weight ) ; assessment cardiovascular specific symptom ; documentation AEs ; concomitant medication ; ECOG-performance status ; central standard ECG cycle 6 ; CT scan MRI ; safety laboratory assessment ( hematology include coagulation parameter biochemistry ) ; serum pregnancy test woman childbearing potential . Blood sample plasma circulate marker maintenance treatment , CTC/CEC ( 6 cycle chemotherapy ) . Final Tumor Assessment Visit ( At occurrence PD and/or start systemic anti-tumor therapy ) : Physical examination include vital sign ( without BSA ) ; documentation AEs ; concomitant medication ; ECOG-performance status ; CT scan MRI ; safety laboratory assessment ( hematology include coagulation parameter biochemistry ) ; blood sample plasma circulate marker CTC/CEC ; serum pregnancy test . End-of-Study ( EoS ) Visit ( Around 28 day last investigational medicinal product [ cilengitide cetuximab ] administration , anticancer treatment start , FTA visit ) : Physical examination include vital sign ( without BSA ) ; documentation AEs . If subject begin subsequent anticancer therapy , AE report period non-serious AEs end time new treatment start ; ECOG-performance status ; concomitant medication ; safety laboratory assessment ( hematology include coagulation parameter biochemistry ) ; blood sample HACA assessment ; central 12-lead ECG ; reason discontinuation . Survival Follow-up ( Every 2 month EoS visit ) : Each subject 's survival status anti-cancer treatment document every 2 month end study visit death , loss follow-up , consent withdrawal . All subject treat platinum-based chemotherapy maximum 6 cycle ( , 18 week ) , PD death , unacceptable toxicity , subject withdraws consent . Subjects experience PD 6 cycle platinum-based treatment continue treatment cilengitide ( Groups A B ) cetuximab ( Group A , B C ) . Subjects discontinue treatment without PD remain study . Response assessment continue every 6 week PD anti-tumor treatment start . Upon occurrence , study medication discontinue final tumor assessment ( FTA ) visit carry . The end-of-study visit perform around 4 week last investigational medicinal product administration FTA visit .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent obtain undergoing studyrelated activity . 2 . Male female , least 18 year age 3 . Histologically confirm NSCLC , Stage IIIb document malignant pleural effusion Stage IV ( accord stag system 6th edition ) 4 . EGFR expression great equal ( &gt; = ) 200 tumor tissue determine local test use kit testing procedure describe study Manual Operations ( MOP ) 5 . Archived tumor material sample central histology biomarker research include mutational analysis gene EGFR , kras , braf ( material detail describe study MOP ) 6 . At least 1 radiographically document measurable lesion previously nonirradiated area accord evaluation criterion solid tumor ( RECIST ) , i.e . lesion must adequately measurable least 1 dimension ( long diameter [ LD ] record ) &gt; =2 centimeter ( cm ) conventional technique ≥1 cm spiral CT scan 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 8 . Leukocyte count &gt; =3.0 x 10^9 per liter ( /L ) 9 . Absolute neutrophil count ( ANC ) &gt; =1.5 x 10^9/L 10 . Platelets &gt; =100 x 10^9/L 11 . Hemoglobin &gt; =9 gram per deciliter ( g/dL ) ( without transfusion ) 12 . Bilirubin le equal ( &lt; = ) 1.5 x upper limit normality ( ULN ) 13 . Aspartate Aminotransferase ( AST ) &lt; =5 x ULN Alanine Aminotransferase ( ALT ) &lt; =5 x ULN 14 . Serum creatinine &lt; =1.25 x ULN and/or creatinine clearance &gt; =60 milliliter per minute ( mL/min ) 15 . Prothrombin time ( PT ) , international normalize ratio ( INR ) within normal limit partial thromboplastin time ( PTT ) upper limit normal . 16 . Sodium potassium within normal limit &lt; =10 % ( supplementation permit ) . 17 . Effective contraception male female subject ( risk conception exists ) . If female , must : neither pregnant breastfeeding , attempt conceive , use highly effective method contraception least 7 day entry trial , throughout entire duration trial 6 month follow completion last dose trial medication . A highly effective method contraception define result low failure rate ( , &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) ( hormonal copperbased ) , sexual abstinence vasectomize partner , postmenopausal surgically sterilize . If male , must willing use contraception avoid pregnancy least 7 day entry trial , throughout entire duration trial 6 month follow last dose trial medication . Two negative semen analyse postvasectomy available order consider infertile Exclusion criterion : 1 . Prior treatment antibody molecule target EGFR and/or vascular endothelial growth factor receptor ( VEGFR ) relate signal pathway 2 . Previous chemotherapy NSCLC include prior adjuvant therapy 3 . History current brain metastasis and/or leptomeningeal disease ( know suspect ) 4 . Radiotherapy ( except localize radiotherapy pain relief ) , major surgery intake investigational drug 30 day start study treatment entry 5 . Concurrent chronic immunosuppressive hormone anticancer therapy ( physiologic hormone replacement corticosteroid treatment chronic obstructive pulmonary disease [ COPD ] allow ) 6 . Clinically relevant coronary artery disease ( New York Heart Association [ NYHA ] functional angina classification III/IV ) , congestive heart failure ( NYHA III/IV ) , clinically relevant cardiomyopathy , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia 7 . History coagulation disorder associate bleeding , recurrent recent thrombotic event history hemoptysis relate bronchopulmonary cancer . Hemoptysis define cough teaspoon red blood per day 8 . Recent peptic ulcer disease ( endoscopically proven gastric , duodenal esophageal ulcer ) within 6 month study treatment start 9 . Presence contraindication treatment cilengitide , cetuximab , cisplatin vinorelbine gemcitabine include : Known hypersensitivity cilengitide , cetuximab , cisplatin , vinorelbine , gemcitabine excipients drug Superior vena cava syndrome contraindicate hydration Symptomatic peripheral neuropathy National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) Grade &gt; =2 and/or ototoxicity NCI CTC AE Grade &gt; =2 , except due trauma mechanical impairment due tumor mass Phenytoin ( introduce prevent anticonvulsant effect certain anticancer drug ) ( contraindication cisplatin ) Yellow Fever Vaccine , Live Attenuated Vaccines ( contraindication cisplatin ) 10 . Pregnancy lactation period 11 . Concurrent treatment nonpermitted drug 12 . Treatment investigational product within past 30 day 13 . Previous malignancy NSCLC last 5 year except basal cell cancer skin preinvasive cancer cervix 14 . Medical psychological condition would permit subject complete study sign inform consent 15 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) 16 . Patients hepatitis , massive liver metastasis ( &gt; 75 % ) , current alcoholism liver cirrhosis ( vinorelbine gemcitabine ) 17 . Patients therapeutically anticoagulated 18 . Legal incapacity limit legal capacity 19 . Significant disease ( example , interstitial lung disease ) , investigator 's opinion , would exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>First-line treatment subject advance NSCLC ,</keyword>
	<keyword>integrin receptor antagonist , EGFR chimerized monoclonal antibody , chemotherapy</keyword>
	<keyword>safety run-in + randomization part , MTD , PFS , Overall survival time , best overall response</keyword>
</DOC>